Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ESSA Pharma Inc EPIX

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a... see more

NDAQ:EPIX - Post Discussion

ESSA Pharma Inc > Level 2 please....
View:
Post by Stock20 on Aug 28, 2019 4:19pm

Level 2 please....

Moving up with very low volume. Can somebody post level 2.
Thanks.
Comment by Stock20 on Sep 16, 2019 9:44pm
CAN SOMEBODY PLEASE POST LEVEL 2.  WILLING TO INVEST MORE HERE. THANKS.
Comment by SilentRiver on Sep 17, 2019 8:49am
$3.90 -$0.00 (0.00%) 3.60 (1) 4.05 (1) 0 0.00 - 0.00 Buy Sell Hide Level Two Quotes # Orders Shares Bid Ask Shares # Orders 1 100 3.600 4.050 100 1  ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities